

Table S1: Serum half-life of immune-checkpoint inhibitors

ICIs	Mechanism of action	Half-Life	Reference
Ipilimumab	Anti CTLA4	14.7 days	[1]
Tremelimumab	Anti CTLA4	19.6 days	[2]
Nivolumab	Anti PD-1	25 days	[3]
Pembrolizumab	Anti PD-1	14-27.3 days	[4]
Cemiplimab	Anti PD-1	12 days	[5]
Toripalimab	Anti PD-1	14.2 days	[6]
Sintilimab	Anti PD-1	35.6 h	[7]
Avelumab	Anti PD-L1	3.9-4.1 days	[8]
Durvalumab	Anti PD-L1	21 days	[9]
Atezolizumab	Anti PD-L1	27 days	[10]

1. Feng, Y.; Masson, E.; Dai, D.; Parker, S.M.; Berman, D.; Roy, A. Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. *Br. J. Clin. Pharmacol.* 2014, 78, 106–117.
2. Camacho, L.H.; Antonia, S.; Sosman, J.; Kirkwood, J.M.; Gajewski, T.F.; Redman, B.; Pavlov, D.; Bulanhagui, C.; Bozon, V.A.; Gomez-Navarro, J.; et al. Phase I/II Trial of Tremelimumab in Patients with Metastatic Melanoma. *J. Clin. Oncol.* 2009, 27, 1075–1081.
3. Bajaj, G.; Wang, X.; Agrawal, S.; Gupta, M.; Roy, A.; Feng, Y. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients with Solid Tumors. *CPT Pharmacomet. Syst. Pharm.* 2017, 6, 58–66.
4. Elassaiss-Schaap, J.; Rossenu, S.; Lindauer, A.; Kang, S.P.; de Greef, R.; Sachs, J.R.; de Alwis, D.P. Using Model-Based “Learn and Confirm” to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial. *CPT Pharmacomet. Syst. Pharm.* 2017, 6, 21–28.
5. Papadopoulos, K.P.; Johnson, M.L.; Lockhart, A.C.; Moore, K.; Falchook, G.S.; Formenti, S.C.; Naing, A.; Carvajal, R.D.; Rosen, L.S.; Weiss, G.J.; et al. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. *Clin. Cancer Res.* 2020, 26, 1025–1033.
6. Yang, J.; Dong, L.; Yang, S.; Han, X.; Han, Y.; Jiang, S.; Yao, J.; Zhang, Z.; Zhang, S.; Liu, P.; et al. Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. *Eur. J. Cancer* 2020, 130, 182–192.
7. Zhang, L.; Mai, W.; Jiang, W.; Geng, Q. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. *Front. Oncol.* 2020, 10, 594558.
8. Heery, C.R.; O’Sullivan-Coyne, G.; Madan, R.A.; Cordes, L.; Rajan, A.; Rauckhorst, M.; Lamping, E.; Oyelakin, I.; Marté, J.L.; Lepone, L.M.; et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): A phase 1a, multicohort, dose-escalation trial. *Lancet. Oncol.* 2017, 18, 587–598.
9. Baverel, P.G.; Dubois, V.F.S.; Jin, C.Y.; Zheng, Y.; Song, X.; Jin, X.; Mukhopadhyay, P.; Gupta, A.; Dennis, P.A.; Ben, Y.; et al. Population Pharmacokinetics of Durvalumab in Cancer Patients and Association with Longitudinal Biomarkers of Disease Status. *Clin. Pharmacol. Ther.* 2018, 103, 631–642.
10. Stroh, M.; Winter, H.; Marchand, M.; Claret, L.; Eppler, S.; Ruppel, J.; Abidoye, O.; Teng, S.L.; Lin, W.T.; Dayog, S.; et al. Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma. *Clin. Pharmacol. Ther.* 2017, 102, 305–312.